|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
April 28, 2006
More Good News for Tysabri:
"An advisory committee to European drug regulators is recommending that Tysabri, the MS drug from Biogen Idec , be returned to the market. The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on the drug, Biogen and Elan said in a press release Friday. The panel arrived at its decision after reviewing data from clinical trials and the results of safety analyses that were performed after Tysabri was linked to a potentially fatal brain disease. The committee specifically suggested that Tysabri should be used to treat recurring MS in order to delay the progression of the disease......" |